UT-MD Anderson Cancer Center: Immunotherapy Before Surgery Leads to Promising Long-Term Survival in Sarcoma Patients
February 15, 2024
February 15, 2024
HOUSTON, Texas, Feb. 15 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas
* * *
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term . . .
* * *
MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas
* * *
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term . . .